Induced Pluripotent Stem Cell (iPSC) Market Anticipated To Witness Robust Growth, Surpassing $5.29 Billion By 2029

The Induced Pluripotent Stem Cell (iPSC) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Induced Pluripotent Stem Cell (iPSC) Market Size and Its Estimated Growth Rate?
The market for induced pluripotent stem cells (iPSC) has seen rapid expansion in recent times, expanding from $3.3 billion in 2024 to approximately $3.67 billion in 2025, at a compound annual growth rate (CAGR) of 11.3%. Several factors account for the growth in the historic time frame, such as increased expenditure on healthcare, increasing funding, heightened consciousness of the healing capabilities of stem cell products, the use of iPSC for drug discovery, growing interest in personalized medicine and the cost-effectiveness of iPSC in drug discovery.

In the coming years, the induced pluripotent stem cell (iPSC) market is predicted to experience significant growth. The market estimation for 2029 is around $5.29 billion, growing at a compound annual growth rate (CAGR) of 9.6%. Factors contributing to this forecasted growth include the rising incidence of chronic and genetic diseases, progression in genomic projects, creation of IPSC-derived disease models, an increase in government initiatives and a rapid technological advancement. The period also forecasts major trends such as the use of pluripotent stem cells in the treatment of Parkinson's disease (PD), strategic collaborations and partnerships, the creation of induced pluripotent stem cell IPSC-derived nk cells and use of iPSC for cell therapy. There will also be increased investment in regenerative medicine research and development, the creation of IPSC expansion medium, the development of custom IPSC, and the use of pluripotent stem cells in the treatment of Type I diabetes.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2515

How Are Emerging Segments Shaping the Induced Pluripotent Stem Cell (iPSC) Market Landscape?
The induced pluripotent stem cell (iPSC) market covered in this report is segmented -

1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types
2) By Application: Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy
3) By End-User: Hospitals, Research Laboratories

Subsegments:
1) By Hepatocytes: iPSC-Derived Liver Cells For Drug Toxicity Testing, Disease Modeling And Regenerative Therapies
2) By Fibroblasts: iPSC-Derived Skin Cells For Wound Healing And Tissue Repair, Fibroblast-Based Disease Research
3) By Keratinocytes: iPSC-Derived Skin Cells For Dermatological Research, Skin Regeneration Therapies
4) By Amniotic Cells: iPSC-Derived Cells For Prenatal Research, Amniotic Fluid-Based Regenerative Applications
5) By Other Derived Cell Types: Neurons For Neurological Disease Modeling, Cardiomyocytes For Heart Disease Studies, Endothelial Cells For Vascular Research

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2515&type=smp

Which Growth Factors Are Influencing Induced Pluripotent Stem Cell (iPSC) Market Expansion?
The escalating occurrence of persistent health conditions is a key contributor to the expansion of the induced pluripotent stem cell market. Diseases such as heart issues, cancer, stroke, and diabetes can be managed using Induced pluripotent stem cells. These cells are procured from any tissue of a child or adult and genetically manipulated to mimic embryonic stem cells. Findings from a report by the Partnership to Fight Chronic Disorder (PFCD) reveal that 45% out of 133 million Americans suffer from at least a single chronic illness. In addition, it was projected that 7 in every 10 deaths in the US, equating to around 1.7 million, stem from chronic illnesses. These deaths can be regulated by induced pluripotent stem cell therapy. The increasing prevalence of these chronic illnesses is thus spurring demand in the induced pluripotent stem cell treatment market.

Who Are the Dominant Players Across Different Induced Pluripotent Stem Cell (iPSC) Market Segments?
Major companies operating in the induced pluripotent stem cell (iPSC) market include FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio, Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart

What Induced Pluripotent Stem Cell (iPSC) Market Trends Are Gaining Traction Across Different Segments?
Businesses within the Induced Pluripotent stem cell market are seeking out strategic alliances and collaborations that will facilitate their penetration into new markets while broadening their product ranges. This was demonstrated in January 2022, when Bristol Myers Squibb and Century Therapeutics came together in a strategic collaboration to create IPSC-derived allogenic cell therapies specifically aimed at treating acute myeloid leukemia and multiple myeloma. Likewise, in May 2022, Evotec and Sernova revealed their strategic partnership aimed at the development of IPSC-based beta cell replacement therapies for treating both type 1 and type 2 diabetes.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report

Which Geographic Regions Are Expected to Dominate the Induced Pluripotent Stem Cell (iPSC) Market in the Coming Years?
North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2024. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (IPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Induced Pluripotent Stem Cell (iPSC) Market?
2. What is the CAGR expected in the Induced Pluripotent Stem Cell (iPSC) Market?
3. What Are the Key Innovations Transforming the Induced Pluripotent Stem Cell (iPSC) Industry?
4. Which Region Is Leading the Induced Pluripotent Stem Cell (iPSC) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.